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Abstract 
The progression of tumours to malignancy is commonly considered to arise through 
lineal evolution, a process in which mutations conferring pro-oncogenic cellular 
phenotypes are acquired by a succession of ever-more dominant clones. However, this 
model is at odds with the persistent polyclonality observed in many cancers. We 
propose that an alternative mechanism for tumour progression, called interclonal 
cooperativity, is likely to play a role at stages of tumour progression when mutations 
cause microenvironmental changes, such as occur with epithelial-mesenchymal 
transitions (EMTs). Interclonal cooperativity occurs when cancer cell-cancer cell 
interactions produce an emergent malignant phenotype from individually non-
malignant clones. In interclonal cooperativity, the oncogenic mutations occur in 
different clones within the tumour that complement each other and cooperate in order 
to drive progression. This reconciles the accepted genetic and evolutionary basis of 
cancers with the observed polyclonality in tumours. Here, we provide a conceptual 
basis for examining the importance of cancer cell-cancer cell interactions to the 
behaviour of tumours and propose specific mechanisms by which clonal diversity in 
tumours, including that provided by EMTs, can drive the progression of tumours to 
malignancy. 
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Tumour progression is a consequence of genetic diversity caused by mutations 
Carcinogenesis progresses in clinical stages that are reflected in discrete behavioral 
(phenotypic) changes in the cells that give rise to the cancer. Underlying this 
progression from normal tissue to pre-malignant tumour to malignant tumour is the 
acquisition of discrete changes in the genomes of the cells that make up the tumour 
[1]. It is generally accepted that these genotypic changes (mutations), in concert with 
the selection of cells with an advantage in survival and proliferation, is what drives 
tumour progression. They may include essentially irreversible changes such as 
substitutions, deletions, amplifications and translocations, as well as metastable 
epigenetic features such as methylation and chromatin structural signatures. The 
mutations that underlie the acquisition of malignant characteristics in tumour cells are 
generally considered to arise within a succession of ever-more dominant clones [2, 3], 
a process that we will refer to as lineal evolution. Lineal evolution predicts that the 
genotypic changes that give rise to the malignant phenotypic changes are cumulative 
within the clone that progresses to full malignancy.  
Each time a tumour cell undergoes a mutation, it adds genetic diversity to the tumour 
cell population, because it becomes genetically distinct from its parent cell, thereby 
creating a new clone. According to lineal evolution, if a mutation is not seriously 
deleterious to the survival and replication of the cell, this added genetic diversity will 
persist until either the resultant clone is outgrown by other clones under some sort of 
selection pressure, such as nutrient limitation, or itself outgrows other clones, thereby 
dominating the tumour [2, 3]. However, during the time before selection eliminates it, 
and for as long as no selection pressure is introduced to discriminate against it, the 
added genetic diversity persists. A direct consequence of this is added phenotypic 
diversity, at least until selection of a dominant clone occurs.  
Phenotypic changes in epithelial cells caused by mutations can result in an epithelial-
mesenchymal transition (EMT), in which epithelial differentiation characteristics of 
gene expression, topology and behaviour are lost and replaced by those more 
commonly associated with mesenchymal cells [4-6]. However, cancer is increasingly 
being appreciated as a disease of stem cells, and part of its phenotypic heterogeneity 
may be caused by the inappropriate implementation of normal differentiation 
programs, which can have lasting phenotypic consequences via epigenetic 
mechanisms. This differentiation program can be initiated by upstream genetic 
alterations and/or by microenvironmental influences [4, 7, 8] and can be reversible [9, 
10].  
Mutations can produce either cell-autonomous or microenvironmental 
phenotypes 
The phenotypes arising from mutations in a cell lineage that allow a tumour to form 
or to progress to malignancy can be either cell-autonomous, having no immediate 
effect on the cells surrounding it, or microenvironmental, affecting both the cell 
bearing the mutation and its neighbouring cells and surrounding extracellular matrix 
(ECM). Examples of phenotypes normally considered to be cell-autonomous are 
resistance to stimuli that induce senescence, apoptosis or terminal differentiation, 
escape from cell-cycle controls and loss of DNA-repair mechanisms, all of which 
generally occur early in tumour development. However, cell-autonomous phenotypes 
can also contribute to cancer pathogenesis in later stages e.g. the acquisition of 
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multidrug resistance through point mutation or amplification of MDR1, which 
encodes a drug efflux pump [11, 12]. In keeping with the lineal evolution model, the 
net effect of each of these cell-autonomous phenotypes is to confer upon the clone 
that acquires them an enhanced ability to proliferate in situ, even following 
therapeutic intervention. This growth advantage over its neighbours allows the clone 
to dominate the tumour. In the case of losing the ability to repair DNA, it also gives 
rise to a higher rate of mutations in subsequent generations, which makes it more 
likely that this clone will acquire beneficial (to the survival of its progeny), as well as 
deleterious, mutations [3].  
A microenvironmental phenotype is a consequence of a mutation that affects not just 
the cell that bears the mutation, but also the neighbouring cells and nearby ECM that 
together constitute its microenvironment. Just as a mutation in a cell can alter its 
effect on its microenvironment, the microenvironment can, in turn, alter that cell [13]. 
It is the cellular component of the microenvironment that will be focussed upon here. 
In tumour cells, pro-oncogenic microenvironmental phenotypes arise from mutations 
that cause the production of a factor that confers advantage on other, nearby cells, as 
well as on the cell that makes the factor. 
Invasion is by definition the spread of cancer cells into their local environment and so, 
not surprisingly, many of the cellular phenotypes that are associated with invasiveness 
are microenvironmental in nature, often relying on the secretion of factors into the 
extracellular space. However, other phenotypes may also be microenvironmental. 
Examples of microenvironmental phenotypes are the angiogenic phenotype, the pro-
inflammatory phenotype and the ECM destructive phenotype. Thus, the acquisition of 
a mutation that causes a cancer cell to secrete an angiogenic factor will promote an 
efficient vasculature that will provide an enhanced nutrient supply and the opportunity 
to grow larger, not only to the cell that makes the factor, but to all other cells in the 
vicinity, including non-mutant cells. A mutation that causes the release of leukocyte 
attracting or activating molecules will encourage an inflammatory environment not 
just for the cancer cells that harbour that mutation, but also for nearby cancer cells 
that lack it. Similarly, the acquisition of a mutation that causes a cell to release 
excessive amounts of ECM-degrading enzymes will result in a more porous ECM that 
will provide an enhanced opportunity to migrate unimpeded into surrounding tissues, 
not only to the cell that makes the enzymes, but also to all other cells in the vicinity. 
Some phenotypes can be either cell-autonomous or microenvironmental, depending 
on the genes that are mutated (Table I). For example, a mutation that provides drug 
resistance by up-regulating the expression of a gene such as MDR1, which pumps 
cytotoxic drugs from the cytoplasm into the extracellular space, would be cell-
autonomous, since it would not benefit any of the cells surrounding it [12]. In 
contrast, a mutation that allowed a cell to inactivate a chemotherapeutic drug 
metabolically, and in so doing cause it to be locally depleted below a therapeutic 
concentration [14], would benefit non-mutant cells in the vicinity, and so the mutation 
would be microenvironmental. A recent study using genetically mosaic mice showed 
that mutations in a single gene can lead to either a cell-autonomous or a 
microenvironmental phenotype, depending on the tissue in which they arise [15].  
Genetic and phenotypic diversity can persist in tumours 
Despite the general acceptance of lineal evolution leading to clonal dominance and 
even monoclonality in neoplasia, genetic diversity (polyclonality) is a common 
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characteristic of tumours [16, 17]. Genetic diversity has been identified using a 
variety of molecular and cytogenetic methods in tumours of the breast [18, 19] and 
other tissues [20-27]. Many of the early studies from which monoclonality gained 
general acceptance may have missed the presence of additional clones due to 
technical limitations: a lack of sensitivity in detecting numerically minor clones, an 
inability to sample small enough areas within tumours in which clones intermingle, or 
the use of mosaic gene expression of inappropriately large patch size [16]. In cases 
where the sequencing of genes in gross tumour specimens has been unable to 
demonstrate any genetic heterogeneity, it has nevertheless been demonstrated by 
using sequencing in conjunction with microdissection and denaturing high pressure 
liquid chromatography analysis [22, 28-30]. Such analyses were not used in earlier 
studies of tumour clonality and still are not used routinely in pathology laboratories.  
Polyclonality within tumours could arise in three ways (Figure 1), each of them 
distinct from lineal evolution (lineage A) and resulting in co-dominant, cooperating 
clones. A single normal cell could give rise to a clone that cooperates with a mutant 
daughter clone, allowing both to be retained in the malignancy (lineage B). 
Alternatively, a single normal cell could mutate into an abnormal precursor clone that 
then bifurcates through distinct subsequent mutations into separate derivative clones 
(lineage C). Alternatively, two or more normal somatic cells could mutate 
independently in parallel and their progeny would mix to form the tumour (lineage 
D). It is not known in general which of these mechanisms most frequently gives rise 
to polyclonality. Studies using mosaicism of X-chromosome inactivation in females 
have been used to address this issue and many have concluded that tumours have their 
origin in a single normal cell. However, this conclusion can not be drawn from such 
studies with any confidence because of a heavy bias towards monoclonality, due to 
the large mosaic patch size of X-chromosome inactivation in relation to the size of the 
tumours [31]. Despite this bias towards monoclonality, this method has sometimes 
identified polyclonality arising from two or more normal cells in tumours of the breast 
[32]. This form of polyclonality was also demonstrated in multiple colonic adenomas 
from a rare XO/XY mosaic human who also had familial adenomatous polyposis [23], 
and in experimentally induced papillomas in chimeric mice [20], where the smaller 
patch sizes in both cases gave less bias towards monoclonality. A definitive answer to 
how often polyclonality has its origins in one or more clones of normal cells may 
await a novel analytical or experimental approach.  
It is often assumed that if a strong enough selection pressure is applied to a tumour 
cell population, then monoclonality will necessarily follow. However, this assumption 
is challenged both by the occurrence of polyclonal tumours in advanced stage cancers 
and by reasoned argument. Whether the number of normal cells from which 
polyclonal tumours originate is one or more than one, it is possible that two or more 
clones could persist in a tumour, even under strong selection pressure, through 
processes analogous to mutualism in the evolution of whole organisms. Moreover, 
cancer is likely to provide the circumstances under which this co-dominance can take 
place, as described below.  
Cancer cell-cancer cell interactions are a consequence of microenvironmental 
phenotypes  
Together, the two aforementioned characteristics of tumours - the presence of 
microenvironmental phenotypes within a tumour, and the phenotypic diversity of 
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cancer cells within it – provide the potential for events to occur that are rarely 
considered in studies of carcinogenesis: cancer cell-cancer cell interactions. 
Interactions can occur between diverse subpopulations of cancer cells that cannot take 
place in a homogeneous population. In cases where interactions between two or more 
phenotypically distinct clones produce an emergent malignant phenotype, interclonal 
cooperativity occurs [33, 34]. Interclonal cooperativity is defined as the state in which 
two or more neoplastic clones display a more malignant phenotype in coexistence 
than in isolation [33, 34]. Thus, clones – none of which are intrinsically invasive and 
metastatic – can interact when they are in proximity to one another in order to become 
invasive and metastatic. In the interclonal cooperativity model of tumour progression, 
not all of the mutations needed for progression are cumulative within a clone, in 
contrast to the lineal evolution model (Figure 1). Moreover, as observed previously 
[33] and discussed below, even a small minority of phenotypically distinct cells can 
have an enormous impact on the behaviour of the population as a whole.  
Interclonal cooperativity is illustrated by the production of collagen-degrading 
activity by the BC1 rat mammary carcinoma cell line in vitro. BC1 is composed of 
two phenotypically distinct cell populations: “E-cells”, which have retained epithelial 
differentiation characteristics, and “M-cells” which are metaplastic, having undergone 
an EMT. Alone, each cell type produces little collagen-degrading activity. However, 
when co-cultured, they produce a large amount of collagen-degrading activity [33, 
34]. The fact that both E-cells and M-cells are needed for the production of collagen-
degrading activity first drew attention to the possibility that interclonal cooperativity 
(originally called biclonal cooperativity) could play a role in the progression of 
tumours to malignancy. The molecular basis underlying this cooperativity is the 
secretion of factors by the E-cells that stimulate secretion of collagen-degrading 
matrix metalloproteinases by the M-cells. The E-cells also secrete factors that 
stimulate growth and attachment of M-cells, whereas the M-cells make large amounts 
of multidrug resistance proteins [34, 35].  
There is also evidence that interclonal cooperativity contributes to metastasis in vivo. 
The BC1 cell line was injected into syngeneic animals to grow tumours, and cell lines 
(“LN”) were established from their lymph node metastases [34]. Lineal evolution 
predicts that the metastases from the LN cell lines should be as large or larger than 
those from the original BC1 cells, because they have been selected for the ability to 
metastasise to the lymph nodes. However, the experimental data do not support this. 
Tumours derived from those LN cell lines produced metastases that were significantly 
smaller than those produced by the original BC1 cell line grown under identical 
conditions, whereas the primary tumours did not differ significantly in size (Figure 2). 
These data are consistent with an interclonal cooperativity taking place in which there 
exists a subpopulation of cells that facilitates the metastasis of other cells within the 
primary tumour, but that does not itself metastasise. Thus, the population of cells that 
has metastasised produces smaller metastases due to the lack of non-metastatic 
facilitator cells in the primary tumours in the LN cell lines.  
A contribution of interclonal cooperativity to metastasis does not require that cells of 
the primary tumour communicate with cells of the secondary tumour; only that 
communication between cells within the primary tumour takes place. Metastasis is a 
multi-stage process, several stages of which interclonal cooperativity could contribute 
to. For example, invasion of the vasculature and detachment from the primary tumour 
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mass could require the production of paracrine factors, as described above. If cells 
that entered the circulation were competent to survive and grow at the secondary site, 
then there would be no need for ongoing exposure to the paracrine factors for 
metastasis to occur. Alternatively, it is conceivable that growth of a clone at a 
secondary site (e.g. lymph node) could require factors that could be provided by other 
cancer clones through paracrine secretion or cell-cell contact, but not by the non-
cancer cells normally resident at the secondary site. In this case, even though the 
clone had reached the secondary site, it would remain dormant as an occult metastasis 
until either cells of a complementary clone also reached its vicinity or a subsequent 
complementary mutation occurred. A scenario similar to this was proposed by Israel 
[36] to explain occult metastases, although it was not clear whether the source of the 
hypothetical paracrine factor was stromal cells or other cancer cells.  
Factors affecting the impact of a microenvironmental phenotype on cancer cell-
cancer cell interactions 
The space in which a microenvironmental phenotype of a cell can affect other cells is 
its field of influence, and is determined by the range over which the factors produced 
by that cell are active (Figure 3). Key to microenvironmental phenotypes is the ability 
of the cell to communicate the phenotype to its neighbours. This is most obviously 
done by the release of diffusible factors that mediate the phenotype, but also could be 
done by direct cell-cell signalling via cell-surface receptor-ligand pairs and 
cytoplasmic continua, or by modifying the ECM in such a way that it lays down 
signals for cells that encounter it subsequently via plasma membrane extrusions or 
gross motility in order to alter their behaviour.  
The strength of a phenotypic field of influence will depend on the nature and amount 
of the phenotype-conferring factor and its interactions with the microenvironment. 
For example, if a high-motility phenotype is conferred on a cell by a mutation 
(MOT+) that causes it to release self-saturating amounts of a chemokine, then the 
strength of its field of influence diminishes with the square of the distance from the 
cell that makes it, in a classical diffusion manner: the further that a neighbouring cell 
that lacks the mutation is located from the source of the chemokine, the less it will 
benefit from it. However, a consequence of the chemokine will be the dispersal of the 
cells that make it, because they will be exposed to the highest concentration. This 
dispersal will tend to ensure that other, non-mutant clones within the tumour are never 
too far from a MOT+ cell, and so all cells within the tumour might end up being 
within a strong field of influence of the clone. This would be mutually antagonistic 
with the cell type partitioning effects that can be conferred by homotypic cell-cell 
adhesion molecules (discussed below). This mixing of the mutant clone with other 
clones in the tumour will be accentuated if the chemokine is also chemotactic. The 
chemotactic feature will have no effect on the direction of migration of the mutant cell 
that produces the factor, because it is at the highest concentration of it; only motility 
will be increased. However, non-mutant cells within the field of influence will tend to 
migrate towards the mutant cells, where the concentration of chemokine is at its 
highest. A consequence of this is that when the mutant clone invades surrounding 
tissues, it will tend to drag a cohort of non-mutant cells with it. Another consequence 
is a rapid blending of the tumour population, with the MOT+ clone becoming 
dispersed amongst MOT- clones. This blending would make the recognition of 
polyclonality using gross histological or genetic procedures extremely difficult. A 
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longer term effect might be the selection of MOT- clones that acquire mutations that 
cause them to respond more strongly to the chemokine e.g. by up-regulating 
chemokine receptors. This would increase their genetic distance and phenotypic 
difference from the MOT+ clone, on which no such selection pressure would exist, 
thereby increasing tumour cell diversity even further.  
The field of influence may also exhibit threshold effects. A special case in point is 
where direct cell-cell contact is responsible for communicating the phenotype arising 
from a mutation in a cell to the cells that surround it. The field of influence will 
extend to exactly one cell diameter outside of the mutant cell (i.e. 1.5 cell diameters 
from the centre of the cell). Inside that, non-mutant tumour cells benefit from the 
phenotype of the mutant cell; outside, they do not. Phenotypes mediated by mutation-
induced diffusible factors can also give rise to threshold effects. For example, 
consider the situation in which penetration of the ECM is rate limiting for the 
expansion of a tumour, and pores of a certain size must be made in the ECM through 
the action of ECM-degrading enzymes in order for tumour cells to invade. When a 
mutation (DEG+) arises that causes the cells to release diffusible ECM-degrading 
enzymes, the porosity of the ECM near the mutant cell will increase to the point 
where the cell is able to migrate through it. Because the enzymes are diffusible, they 
will degrade the ECM further from the cell, also, albeit to a lesser extent, due to the 
concentration of enzymes diminishing with distance from the cell. As a consequence 
of the gradient of ECM-degrading enzymes radiating from the DEG+ cell, a gradient 
of ECM porosity is established, with the ECM closest to the DEG+ cell being most 
porous. As one moves further from a cell, a distance from the DEG+ cell is reached 
where the porosity of ECM is just insufficient for cells to be able to migrate through 
it. Neighbouring DEG- cells within this distance will be able to invade the ECM, 
whereas those outside this distance will be unable. The concentrations of diffusible 
factors would be expected to drop to zero where blood or lymphatic vasculature is 
encountered, because it would diffuse into the vascular fluid and be carried away.  
Combinations of gradients and thresholds also have the potential to occur e.g. where a 
phenotype is mediated by a mutation that causes the release of a diffusible factor that 
can be inactivated by binding irreversibly to an inhibitor that is present in the tissues. 
In this case, the strength of the field of influence will diminish with distance from the 
mutant cell until its concentration is equal to that of the inhibitor, when it becomes 
zero. Molecules that compete for these inhibitors, activators or co-factors could also 
regulate the field of influence of a phenotype, and these might be affected by other 
mutations. Clearly, as the number of mutations and/or extracellular factors involved 
increase above a very few, the complexity of the interactions makes accurate 
predictions of tumour behaviour based on intuition unreliable; mathematical 
modelling becomes essential [37].  
The contribution of EMT to cancer cell diversity and its microenvironmental 
consequences 
EMT is an attractive mechanism for contributing to interclonal cooperativity in 
tumours because the phenotypic changes that it induces are so dramatic, and because 
many of them are microenvironmental in nature. Mesenchymal-epithelial interactions 
have profound effects during normal development [38] and some of these might occur 
between tumour cells that have undergone an EMT and those that have retained 
epithelial differentiation characteristics, thereby contributing to malignancy. Indeed, 
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EMT-like changes have been observed in cancers of the breast and other tissues that 
are in the process of invading and metastasising [5, 39]. The contribution of EMT to 
the heterogeneity of carcinomas is probably underestimated. When the cancer cell 
component of carcinomas is identified using mainly morphological criteria or 
epithelial differentiation markers, there is a possibility that cancer cells that have 
undergone an EMT are overlooked and considered erroneously to be non-malignant 
“stromal” cells, particularly when they constitute a numerically minor component of 
the tumour cell population. As demonstrated in the BC1 model [33] a minor 
subpopulation of cells that have undergone an EMT, constituting only 10% of the 
total, can have a marked effect on the ECM-degrading activity of the cancer cell 
population as a whole. The lower limit of the size of this minority population that 
confers an ECM-degrading activity on the population as a whole was not determined 
in that study, but may be even lower than 10%, which would make them even more 
likely to be overlooked or misidentified. The immortalised NMuMG mouse mammary 
cell line also displays heterogeneity, both in baseline morphology and in EMT-like 
response to transforming growth factor beta and ras oncogenes [40](and Lyons, 
unpublished observations). In human breast cancers, heterogeneity of cadherin 
switching within mammary tumours has been observed, indicating either a sustained 
diversity of epithelial differentiation status or the occurrence of a reversible EMT 
[41]. The potential to overlook numerically minor subpopulations of carcinoma cells 
that have undergone an EMT was demonstrated comprehensively in human breast 
cancer, in which cells that are phenotypically fibroblasts in almost every way can be 
generated from malignant mammary epithelial cells through an EMT [42]. It required 
thorough genetic analyses to be able to distinguish these fibroblast-like cancer cells 
from normal stromal cells and to establish a carcinoma origin for them. Although the 
biological properties of the carcinoma-derived fibroblast-like cells were not examined 
in detail, it is conceivable that they could have combined properties typical of 
fibroblasts, such as matrix metalloproteinase inducibility, with properties typical of 
carcinoma cells, such as unlimited proliferation. Another form of plasticity, 
vasculogenic mimicry [43] may also make it difficult to identify metaplastic cancer 
cells using conventional histopathological methods.  
A number of cell signalling pathways that are activated by genetic alterations 
common in carcinomas can cause an EMT, including those that operate through ras, 
src, SMADs, E-box binding repressors (Snails and ZEBs), beta-catenin and NF-
kappaB [44-50]. Many of these pathways produce microenvironmental phenotypes 
that accompany the EMT, due to changes that they induce in the secretion of growth 
factors, cytokines, chemokines, lytic enzymes, ECM, etc. Particular characteristics of 
EMT would be expected to favour the selection of mutations that both give rise to 
EMT and contribute to clonal diversity in carcinomas. These pro-oncogenic 
characteristics include increased motility, reduced cell-cell contact and inducibility of 
a broad range of ECM-degrading proteinases, as occurs in the BC1 mammary 
carcinoma [34]. However, the acquisition of these properties by undergoing an EMT 
might come with a trade-off, by losing complementary pro-oncogenic properties e.g. 
autonomy of proliferation in cells that maintain an epithelial phenotype, through the 
autocrine secretion of growth factors [33]. Such a loss of complementary properties 
would occur either if the genetic changes conferring proliferative autonomy are 
mutually incompatible with the EMT-inducing genes, or if they arise from the 
deletion or inactivation of a chromosomal region that includes the EMT-inducing 
genes. In either case, the fastest and most probable way to acquire both 
Lyons et al. Clonal diversity and tumour progression  Page 9 of 24 
Clin Exp Metastasis. 2007 Dec 11; [Epub ahead of print] PMID: 18071912 
complementary mutations in a tumour would be for them to occur in different but 
nearby cells within the cancer cell population, thereby maintaining both populations 
of cells: those that maintain an epithelial phenotype and secrete growth factors and 
those that break down ECM.  
When are tumours more likely to progress by interclonal cooperativity than by 
lineal evolution? 
To illustrate the impact that the microenvironmental nature of a phenotype and 
consequent interclonal cooperativity can have on tumour progression, consider the 
example in which two mutations are required to cause a tumour to progress to 
malignancy, and both mutations are independent and equally likely to occur. If the 
phenotypes arising from both mutations are cell-autonomous and so must occur in the 
same cell, then progression can only take place through lineal evolution. If, however, 
one of the mutations produces a microenvironmental phenotype, then progression can 
take place through either lineal evolution or interclonal cooperativity. To compare the 
two modes of evolution, we may ask the question: how many instances of two 
mutations occurring within 10 cell diameters do we expect to occur in a tumour, 
compared with the two mutations occurring in the same cell? If we assume that the 
cells are non-deformable, regularly packed spheres in a cubic lattice array, then 5,569 
cells will fall within the field of influence (Figure 3); this number will underestimate 
the case in most real tumours, in which cells are deformable and are likely to have 
higher packing densities. Now, let the probability of both mutations occurring within 
the same cell be PLE and the probability of progression proceeding by that mutation 
occurring in two different cells be PIC. Then PIC = 1 - (1-M)n-1, where n is the number 
of cells within the field of influence of the microenvironmental phenotype and M is 
the mutation frequency. For low mutation rates of 10-6 to 10-7, similar to normal cells 
[51], the probability of the mutations occurring anywhere within the field of influence 
in the next round of cell division will be greater than the probability of them occurring 
within a single cell by, approximately, the number of other cells within the field of 
influence. To express it another way, a cancer that arises from a benign tumour by 
acquiring two low frequency mutations, at least one of which has a 
microenvironmental range of activity of 10 cell diameters, is 5,568 times more likely 
to have progressed to malignancy through interclonal cooperativity than through 
lineal evolution. The likelihood that the cancer will be biclonal, rather than 
monoclonal, will be correspondingly higher.  
The impact of interclonal cooperativity decreases with increasing mutation frequency 
(Figure 4) but, even at a very high mutation frequency of 10-2, there is still a 100-fold 
higher expectation that the tumour will progress through interclonal cooperativity for 
this range of activity. As the range of activity decreases, the likelihood of interclonal 
cooperativity being responsible for progression also decreases. Nevertheless, even 
when the microenvironmental phenotype operates over a range of activity of just 2 
cell diameters and appears with a very high mutation frequency of 10-2 in a low 
efficiency cubic lattice packing arrangement, there is still a ~70-fold bias towards 
interclonal cooperativity being the mechanism of progression. When interclonal 
cooperativity requires direct cell-cell contact (i.e. a range of activity of 0 cell 
diameters) and the mutation that gives rise to it appears with a very high frequency of 
10-2, there is a ~6-fold higher likelihood of progressing through interclonal 
cooperativity than through lineal evolution under these conditions.  
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This example assumes an almost simultaneous acquisition of both mutations, which 
may not be the case in vivo. Another limitation is that it does not take into account the 
relative abundance of genes that can give rise to cell-autonomous versus 
microenvironmental phenotypes. Nevertheless, it illustrates the point that, for 
mutations that confer a microenvironmental phenotype on cells, progression can occur 
early through interclonal cooperativity prior to clonal dominance conferred by one of 
the mutations. Moreover, when both mutations have occurred in two separate but 
interacting clones, co-dominance of the clones will ensue, producing a polyclonality 
that is stable, because there will no longer be any selection pressure to drive the 
tumour towards monoclonality for both mutations. Importantly, unlike lineal 
evolution, interclonal cooperativity does not rely on the assumption that every 
mutation on the road to malignancy must confer an advantage on the clone that 
acquires it over the preceding lineage, thereby leading to clonal dominance. Mutations 
whose conferral of advantage rely on other mutations, potentially in a mutually reliant 
way, need not be selected against in interclonal cooperativity, whereas they would be 
extinguished in a progression model driven by clonal dominance. This would permit a 
degree of flexibility in the temporal order of acquisition of mutations that could not 
occur in lineal evolution. This temporal flexibility would itself increase the odds in 
favour of progression through interclonal cooperativity and has been observed in the 
progression of Barrett’s oesophagus to adenocarcinoma [52].  
There can even be circumstances where the probability of two mutations occurring in 
the same cell is zero, due to them having mutually incompatible effects on that cell. In 
these circumstances, the probability of progression through lineal evolution would 
also be zero – interclonal cooperativity would be mandatory for progression to take 
place. One such scenario, where the formation of polyclonal tumours would be 
strongly favoured, is where the effects of two or more mutations that have 
complementary, pro-oncogenic, microenvironmental phenotypes are mutually 
incompatible within a single cell, due to conflicting cell-autonomous side-effects. 
Take, for example, the scenario in which two additional microenvironmental 
phenotypes are needed for a tumour to progress to malignancy, and mutations in gene 
A and gene B produce these phenotypes (Figure 5). However, the intracellular 
signalling pathway activated by A has the side-effect of down-regulating the 
signalling pathway activated by B. In this scenario, cells that are already mutant in A 
will not acquire a selective advantage by acquiring a mutation in B, because mutation 
A will counteract the phenotype conferred by mutation B (Figure 5a). Not only will 
the acquisition of the second mutation in the same cell not be selected for, it will be 
selected against. In contrast, if a mutation in B occurs in a cell within the field of 
influence of the cell that is mutant for gene A (Figure 5b), then it will have a strong 
selection advantage, because the two mutations will be mutually compatible, due to 
their locations in different cells, and complementary, due to their distinct 
microenvironmental effects.  
The extensive feedback and cross-talk between pro-oncogenic signalling pathways 
make such a scenario not unlikely. An example where this might occur is breast 
cancer, in which mutations in p53 and PTEN tend to be mutually exclusive within 
microdissected regions, both in the epithelial and the stromal compartments [53]; the 
possibility that cells within the stromal compartment arose as a result of an EMT was 
not explored in that study. Whether the mutual exclusivity of the p53 and PTEN 
mutations is a result of selection against cells bearing both mutations due to biological 
Lyons et al. Clonal diversity and tumour progression  Page 11 of 24 
Clin Exp Metastasis. 2007 Dec 11; [Epub ahead of print] PMID: 18071912 
incompatibilities between them, or simply a parallel evolution due to redundancy in 
their effects, is not known. However, the distinct intracellular locations and 
biochemical activities of these two tumour suppressor genes would make a complete 
redundancy unlikely.  
Evidence for and against lineal evolution and interclonal cooperativity 
Support for the acquisition of invasion and metastasis by lineal evolution has come 
from several investigations that have derived intrinsically metastatic clones from 
polyclonal tumour populations. A clone is intrinsically invasive or metastatic if it is 
self-sufficient for all of the requirements for invasion or metastasis, in the absence of 
other clones, as would be expected to result from lineal evolution. Using lung 
colonization by injected B16 mouse melanoma cells as a model, it was demonstrated 
that an intrinsically highly metastatic cell line could be derived from a less metastatic 
cell line by repeated cycles of metastasis i.e. by re-injecting cells derived from 
metastases [54-57]. Other studies [58-60] suggested that selection of metastatic cells 
can occur even within the primary tumour and come to dominate it.  
Although the B16 melanoma and similar models [61] have been very useful for 
studying certain aspects of metastasis, they differ from human cancers, in which 
metastases do not arise from metastatic cycling. The number of population doublings 
in which mutations can take place and the amount of time spent under selection 
pressures is obviously greater in the cells selected from 10 cycles of metastasis than in 
an original primary tumour. Correspondingly, the mechanisms of metastasis that 
evolve after 10 previous cycles of metastasis may be quite different from those of the 
original primary tumour. Thus, although the B16 melanoma studies showed that 
intrinsically metastatic clones can be selected for by metastatic cycling, it does not 
necessarily follow that intrinsically metastatic cells do make the dominant 
contribution to metastatic burden originating from a primary tumour. Even in the B16 
melanoma model, polyclonality in metastases has been demonstrated, and done so 
using relatively insensitive methods that may have missed minor clonal populations 
[62]. Moreover, in addition to the data in Figure 2, several studies have challenged the 
generality of the idea that the metastatic phenotype is selected for in clones of the 
primary tumour or even in metastases [63-66]. Thus, the literature indicates that 
metastatic clones are sometimes selected for in a way consistent with a lineal 
evolution model of progression, and sometimes they are not. One explanation offered 
to reconcile the lineal evolution model with this frequent inability to detect selection 
of a highly metastatic phenotype in metastases is that a cell acquires an intrinsic 
metastatic phenotype and then, following metastasis, loses it due to a high rate of 
genetic instability [67, 68]. An alternative explanation is that, similar to the situation 
in the BC1 system, there are subpopulations of cells within the primary tumour that 
take part in the metastatic process by facilitating metastasis of other subpopulations, 
but that do not themselves metastasise.  
Apart from the studies in the BC1 system described above, there is other evidence for 
interactions occurring between phenotypically distinct clones of tumour cells. 
Multiclonal interactions can cause the stabilization of the metastatic phenotype [55], 
growth suppression [69, 70], the transmission of drug resistance [71, 72] and lung 
colonization following intravenous injection [73]. In the last-mentioned study, a cell 
line with no intrinsic metastasising ability was found to accumulate in metastases, 
provided that an intrinsically metastatic cell line was co-injected. An investigation of 
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Kaposi’s sarcoma herpes virus showed that tumour size and incidence increased when 
vGPCR-transformed endothelial cells were co-administered with endothelial cells that 
had been transfected with other viral genes, consistent with the mosaic pattern of 
expression of these genes in human Kaposi sarcomas [74]. A recent study of Barrett’s 
oesophagus [75], a pre-malignant condition in which stratified squamous epithelium 
transdifferentiates into glandular epithelium, demonstrated a correlation between high 
genetic diversity and progression to adenocarcinoma – more homogeneous tumours 
were less likely to progress. Although it was postulated in that paper that the 
contribution of polyclonality to progression was passive, merely providing a greater 
diversity of clones from which to select, it is also consistent with cancer cell-cancer 
cell interactions driving progression.   
Tumour cell diversity: a case for mathematical modelling to help understand its 
implications and make predictions of tumour behaviour 
Mathematical modelling is becoming increasingly important in cancer research to 
‘elucidate the fundamental mechanisms of cancer progression and either to improve 
the therapeutic techniques currently used or to stimulate the development of new 
strategies’ [76]. The advantages that mathematical modelling brings to the field of 
tumour growth are two-fold. Firstly, models foster greater insights into the underlying 
dynamics of a system, especially in complex systems such as carcinogenesis where 
the dynamics are not readily apparent. Secondly, simulations can give a preliminary 
guide to experimental research. Here we focus on the former and discuss models that 
explore the effects of loss of cell adhesion and of increased cell motility. These are 
two important characteristics of cells undergoing EMT. 
Various mathematical models have been created in which the role of cell adhesion in 
tumour progression has been studied. Many of these models examine a heterogeneous 
cell population, which is consistent with experimental findings. In all of these models, 
however, the underlying assumption is that the mutation sequence is linear, so that 
cells do not undergo interclonal cooperativity; different cell lineages are considered to 
be in competition, never in cooperation. Recent examples [77-79] have implicated 
nutrient depletion as a driving force for invasion. In his model [78], Anderson 
considered a heterogeneous cell population in ECM that is homogeneous, 
heterogeneous or randomly distributed. The behaviour of the system was examined 
when there were four as well as one hundred different phenotypes, each with different 
levels of cell adhesion. Although different cancer cell phenotypes were considered, 
cooperation towards malignancy was not. The results of the model showed that 
similar patterns of progression were obtained in the case of four as well as one 
hundred phenotypes, suggesting that useful analysis can be carried out without 
needing to incorporate a large number of phenotypes.  
Models with a small number of phenotypes have an advantage in the study of 
interclonal cooperativity because of the rapid growth of the number of cell-cell 
interactions with the number of phenotypes. In fact, for every n phenotypes in a 
tumour, there are of the order of  n2 different cell-cell interactions. Hence it is 
desirable to use the smallest appropriate number of phenotypes in the model. Such a 
model would be computationally tractable while still exhibiting behaviour unique to 
interclonal cooperativity and reflecting the complexity observed in experimental 
findings. 
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Analysis of cell-cell interactions in cancer could be enhanced further through the 
study of cell sorting behaviour. Experiments by Steinberg [80, 81] showed that a 
heterogeneous mixture of embryonic cells reverted to particular configurations, 
regardless of the initial configuration. While it is possible that not all cell types 
behave similarly, aptly chosen phenotypes may be chosen that exhibit this behaviour. 
Thus, analysis of interclonal cooperativity could be systematically simplified to the 
limited configurations that occur. 
A model developed by Armstrong et al. [82] based on cell adhesion captures this 
behaviour. In the model, two interacting populations are considered including both 
self-population adhesion as well as cross-population adhesion. Interclonal 
cooperativity can be thought of as an advance of this phenomenon. Instead of two 
phenotypes merely coexisting in equilibrium, the different phenotypes cooperate to 
drive tumour progression. 
Another characteristic of EMT is an increase in cell motility. Despite recent efforts 
such as the introductory paper by Coskun et al. [83], which underlines the importance 
of cell motility in progression towards malignancy, this field of study is relatively 
unexplored (reviewed in [84]). Indeed, modelling has the potential to be particularly 
useful in the study of cell motility because mechanisms of cell movement are 
complicated and experiments may be expensive and difficult. In this context 
mathematical models may provide insight into cell behavior and help with the 
analysis and interpretation of experimental data [83]. 
In this paper, we provide a simple introductory model that illustrates the effect of 
interclonal cooperativity as a driving force in tumour progression. The development 
of mathematical models that include both the loss of cell adhesion and increased cell 
motility will be important in the study of interclonal cooperativity, as both of these 
factors play an important role in the path towards malignancy. In the future, clonal 
analysis of oncogene expression in tumour specimens, together with mathematical 
modelling, may be used to devise improved therapies for treating cancer, by taking 
into account the diversity of cellular phenotypes and the complexity of cell-cell 
interactions that occur in malignant tumours. 
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Table I. Cell-autonomous versus microenvironmental phenotypes. 
 
 
Phenotype Cell-autonomous change Microenvironmental 
change 
Proliferation Activating mutation of a 
growth factor receptor 
Up-regulation of a secreted 
growth factor 
Evasion of immune 
surveillance 
Deletion of a tumour 
specific antigen gene 
Secretion of 
immunosuppressive 
cytokines 
Cytotoxic drug resistance Up-regulation of drug 
efflux type multidrug 
resistance genes 
Up-regulation of drug 
metabolising genes 
Reduced cell-cell adhesion Down-regulation of cell 
adhesion molecules 
Up-regulation of 
proteinases that degrade 
cell adhesion molecules 
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Figure 1.  
Schematic representation of lineages that give rise to a malignant tumour by 
lineal evolution (A) and interclonal cooperativity (B, C and D).  
 
 
 
 
 
 
In A, mutation and selection results in a tumour in which all of the mutations required 
for malignancy accumulate in the final dominant clone, whereas in B, C and D, co-
dominant, non-malignant clones arise that persist in the final tumour and cooperate in 
order to manifest an emergent malignant phenotype. In A, B and C, the cancer cell 
lineage(s) has its origins in a single normal cell, whereas in D they arise from more 
than one normal cell. In B, C and D, the malignant status of each clone is dependent 
on the presence of its complementary clone.  
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Figure 2.  
Cells derived from lymph node metastases do not have enhanced metastatic 
capacity.  
 
 
 
 
 
Cells (0.5 X 106) from BC1 or LN cell lines derived from BC1 lymph node metastases 
were injected into the footpad of recipient syngeneic rats and allowed to grow for 40 
days, at which time the animals were euthanased and their popliteal lymph node 
metastases and primary tumours were weighed. The tumour masses and their medians 
are shown. ** p < 0.01 by Mann-Whitney U-test. 
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Figure 3:  
The number of cells lying within the field of influence of a microenvironmental 
phenotype.  
 
 
 
 
 
 
 
A cancer cell in a tumour (grey) acquires a mutation that causes it to secrete a factor 
such that its concentration 10 cell diameters (10D) away is just high enough to exert 
its effect on neighbouring cancer cells. Beyond that, the concentration is too low. 
Thus, cells located entirely within a sphere of 11.5D radius will contact a 
sufficiently high concentration of the factor to be affected by it. Any cell entirely 
within this spherical field of influence that requires the factor in order to progress to 
malignancy will be able to do so – not just the cell that secretes the factor.  
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Figure 4:  
Tumour progression through mutations with a microenvironmental phenotype 
is much more likely to occur through interclonal cooperativity than lineal 
evolution.  
 
 
 
 
 
The mutation frequency and range of activity of a microenvironmental phenotype 
were adjusted to determine what impact they have on the likelihood that a pre-
malignant tumour progresses by interclonal cooperativity, compared with lineal 
evolution. The tumour requires two complementary, mutually compatible 
mutations in order to progress to malignancy, one of which produces a 
microenvironmental phenotype. The expectation of the mutations occurring in two 
different cell within the range of activity of that phenotype, relative to them 
occurring within a single cell (PIC/PLE), is given by the equation:   
where M is the mutation frequency and n is the number of cells within the field of 
influence. The outcomes for 3 different ranges of activity are shown. A range of 
zero means that direct cell-cell contact is required for interclonal cooperativity.  
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Figure 5. 
Malignancy requiring mutually incompatible mutations can only progress 
through interclonal cooperativity. 
 
 
 
 
 
A pre-malignant lesion requires two more mutations that have microenvironmental 
phenotypes in order to progress to malignancy. However, the mutation in gene A 
also has the cell-autonomous phenotype of blocking the phenotype caused by the 
mutation in gene B. If both mutations occur in the same cell, as depicted in (a), 
progression will not occur, because the cell will only display phenotype A. 
However, if the mutations occur in two different cells within the range of activity 
of both microenvironmental phenotypes (b), then progression will occur, because 
both cells will be subject to both phenotypes.  
